NCT07532148Not yet recruitingPhase 1
Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Multicenter, Randomized, Open-Label, 2-Period Crossover Study to Evaluate Pharmacokinetics, Safety, and Tolerability of CKD-215 and D215 in Adults With Advanced BRCA-Mutated Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Source: ClinicalTrials.gov · Last updated 15 Apr 2026
Brief summary (registry, in English)
Clinical Trial to evaluate the pharmacokinetic Characteristics, safety and Tolerability among CKD-215 and D215
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- First submitted
- 9 Apr 2026
- Start date
- 1 Jun 2026
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- Chong Kun Dang Pharmaceutical
- Diseases
- Ovarian cancer
- NCT number
- NCT07532148
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 24
- From 1 Jun 2026 to the primary completion date, 30 Jun 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Have a gastrointestinal disease(Crohn's disease, ulcer etc.) history that can effect drug absorption or surgery
Other
- Patients with central nervous system metastases, unless clinically stable after treatment
- CTCAE Grade 3 or higher adverse events(e.g., anemia, neutropenia, dysgeusia, cough, leukopenia, thrombocytopenia) related to D215
- Subjects who are unable to participate in this clinical trial at the discretion of the investigator
Who the study is looking for
- Between 19 aged and 75 aged in patients with advanced BRCA-mutated high-grade epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer
- 18.0kg/m2≤body mass index(BMI)≤28.0kg/m2
Age in the registry: 19 years to 75 years · Sex: Female · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.